scholarly journals Endometrial stem cells expansion capability for local and systemic routes of administration in a model of experimentally injured endometrium

2016 ◽  
Vol 65 (1) ◽  
pp. 62-68
Author(s):  
Elena O Usoltceva ◽  
Liailia Kh Dzhemlikhanova ◽  
Dariko A Niauri ◽  
Igor Yu Kogan ◽  
Alexander M Gzgzyan
Keyword(s):  
Stem Cells ◽  
Surgical Techniques ◽  
Route Of Administration ◽  
Therapeutic Effects ◽  
Animal Group ◽  
Intravenous Injections ◽  
Routes Of Administration ◽  
Endometrial Stem Cells ◽  
Group A ◽  
Experimental Group

Endometrial stem cells due to their therapeutic characteristics could to be an effective tool of cell technologies in reproductive medicine. The aim of the study was to determine the most therapeutically effective route of administration for endometrial stem cells suspension. The study was conducted in approved animal model of injured endometrium. To create the experimental model tissue pieces of autologous endometrium were implanted on the anterior abdominal wall peritoneum using general surgical techniques. Experimental group animals were treated with endometrial stem cells suspension; in the control animal group a placebo was used. Local and systemic routes of endometrial stem cells administration were compared. The direct injections of stem cells suspension in the endometrial implants were used as the local route of administration, the intravenous injections of stem cells suspension were used as a systemic route. Endometrial stem cells expansion didn’t depend on the routes of administration, whereas therapeutic effects of stem cells was more obvious in tissue pieces after local injection of stem cells.

scholarly journals Tryptophanyl-tRNA Synthetase, a Novel Damage-Induced Cytokine, Significantly Increases the Therapeutic Effects of Endometrial Stem Cells

2020 ◽  
Vol 28 (11) ◽  
pp. 2458-2472
Author(s):  
Se-Ra Park ◽  
Soo-Rim Kim ◽  
Jae-Been Im ◽  
Soyi Lim ◽  
In-Sun Hong
Keyword(s):  
Stem Cells ◽  
Trna Synthetase ◽  
Therapeutic Effects ◽  
Endometrial Stem Cells

scholarly journals Therapeutic effects of Ozone therapy in adult periodontitis treatment, subtypes I and II.

2015 ◽  
Vol 1 (1) ◽  
Author(s):  
Judit Martinez-Abreu ◽  
Mark T Weisser ◽  
Silvia Menendez-Cepero
Keyword(s):  
Adverse Events ◽  
Phase Iii ◽  
Therapeutic Effects ◽  
Type I ◽  
Ozone Therapy ◽  
Group A ◽  
Group B ◽  
Group D ◽  
Experimental Group ◽  
Trial Phase

Introduction. Conventional treatments of the periodontitis rely on surgery and antibioticotherapy. The properties of the ozone offer a more innocuous and more economic new alternative therapeutic. Objective. To evaluate the effectiveness of the ozone therapy in the treatment of periodontitis type I and II, and to identify the adverse events. Methods. It was carried out a clinical trial, phase III, randomized, controlled and to simple blind in patients that went to Odontological Clinic “III Congress of PCC” of Matanzas, January 2013 – January 2015. The sample belonged to 50 patients, divided in 5 groups of 10 patients each one: Group A – Treaties with ozone gas. Group B – OLEOZON®. Group C – ozonized water. Group D – treatment of ozone combined with the three modalities (gas, ozonized water and OLEOZON®. Group Z (control) – conventional treatment. The groups A, B, C and D were the experimental groups. Clinic and microbiolgical evaluation was measures. Effectiveness of the treatment, and adverse events were evaluated. The results showed up in graphics, the percentage and Square Chi were used. The ethical principles were completed. Results. Clinical evaluation went satisfactory to the month of the treatment in 84,6% of the studied places, with better results in the group D (96%), with significant differences between the experimental groups and the control. The microbiological evaluation was satisfactory and increased to 85,4% to the six months of the study. The experimental group D prevailed (96,6%). The effectiveness was good in 85,4% of the sample, prevailing in the experimental group D with 96,6%, followed by the group A. The percentage of adverse events was low, 1,5%. Conclusions. The clinical and microbiological evaluation showed satisfactory results, associated to a low percentage of adverse events (with gas ozone only). The combined ozone therapy was the most effective treatment for this type of periodontitis.

scholarly journals The impact of recipient age on the effects of umbilical cord mesenchymal stem cells on HBV-related acute-on-chronic liver failure and liver cirrhosis

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Ka Zhang ◽  
Haixia Sun ◽  
Huijuan Cao ◽  
Yifan Jia ◽  
Xin Shu ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Liver Cirrhosis ◽  
Liver Failure ◽  
Chronic Liver ◽  
Therapeutic Effects ◽  
Chronic Liver Failure ◽  
Group A ◽  
Recipient Age ◽  
Group D

Abstract Background The results of a previous study verified that umbilical cord mesenchymal stem cells (UCMSCs) have good therapeutic effects for the treatment of HBV-related acute-on-chronic liver failure (ACLF) and liver cirrhosis (LC). Nevertheless, it is still unknown whether the effects of UCMSCs are affected by recipient age. Methods Patients treated with UCMSCs who met the criteria of HBV-related ACLF and liver cirrhosis were identified in this retrospective observational study. Patients were divided into subgroups according to the World Health Organization (WHO) age criteria (< 45 vs. ≥ 45 years). Group A included young ACLF patients (< 45 y), and group B included older ACLF patients (≥ 45 y). Young LC patients (< 45 y) were assigned to group C, and group D included older LC patients (≥ 45 y). Patients’ clinical characteristics, demographics, biochemical factors, and model for end-stage liver disease (MELD) scores were compared for 24 weeks. Results Sixty-four ACLF patients and 59 LC patients were enrolled in this study. Compared with patients in groups B and C, patients in group A did not show significant superiority in terms of the levels of ALT, AST, TBIL, AFP, and PTA and MELD scores. However, the median decrease and cumulative decrease in the TBIL and ALT levels of patients in group C were larger than those of patients in group D after four weeks of UCMSC transfusions. For older patients (≥ 45 y), the cumulative decrease and the median decrease in the TBIL of ACLF patients were significantly greater than those of LC patients after UCMSC treatment. However, the median decrease in ALT levels of ACLF patients was significantly greater than that of LC patients during UCMSC treatment, and the cumulative decrease in ALT levels of ACLF patients was significantly greater than that of LC patients at all time points. Conclusion The therapeutic effects of UCMSCs for HBV-related acute-on-chronic liver failure and liver cirrhosis varied partly by patient age. Assessing patient age is necessary prior to UCMSC clinical use.

scholarly journals The impact of recipient age on the effects of umbilical cord mesenchymal stem cells on HBV- related acute-on-chronic liver failure and liver cirrhosis

2021 ◽  
Author(s):  
Ka Zhang ◽  
Haixia Sun ◽  
Huijuan Cao ◽  
Yifan Jia ◽  
Xin Shu ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Liver Cirrhosis ◽  
Liver Failure ◽  
Chronic Liver ◽  
Therapeutic Effects ◽  
Chronic Liver Failure ◽  
Group A ◽  
Recipient Age ◽  
Group D

Abstract Background The results of a previous study verified that umbilical cord mesenchymal stem cells (UCMSCs) have good therapeutic effects for the treatment of HBV-related acute-on-chronic liver failure (ACLF) and liver cirrhosis (LC). Nevertheless, it is still unknown whether the effects of UCMSCs are affected by recipient age. Methods Patients treated with UCMSCs who met the criteria of HBV-related ACLF and liver cirrhosis were identified in this retrospective observational study. Patients were divided into subgroups according to the World Health Organization (WHO) age criteria (< 45 vs. ≥45 years). Group A included young ACLF patients (< 45 y), and group B included older ACLF patients (≥ 45 y). Young LC patients (< 45 y) were assigned to group C, and group D included older LC patients (≥ 45 y). Patients’ clinical characteristics, demographics, biochemical factors, and model for end-stage liver disease (MELD) scores were compared for 24 weeks. Results Sixty-four ACLF patients and 59 LC patients were enrolled in this study. Compared with patients in groups B and C, patients in group A did not show significant superiority in terms of the levels of ALT, AST, TBIL, AFP, and PTA and MELD scores. However, the median decrease and cumulative decrease in the TBIL and ALT levels of patients in group C were larger than those of patients in group D after four weeks of UCMSC transfusions. For older patients (≥ 45 y), the cumulative decrease and the median decrease in the TBIL of ACLF patients were significantly greater than those of LC patients after UCMSC treatment. However, the median decrease in ALT levels of ACLF patients was significantly greater than that of LC patients during UCMSC treatment, and the cumulative decrease in ALT levels of ACLF patients was significantly greater than that of LC patients at all time points. Conclusion The therapeutic effects of UCMSCs for HBV-related acute-on-chronic liver failure and liver cirrhosis varied partly by patient age. Assessing patient age is necessary prior to UCMSC clinical use.

Therapeutic Potential of Amniotic Fluid Derived Mesenchymal Stem Cells Based on their Differentiation Capacity and Immunomodulatory Properties

2019 ◽  
Vol 14 (4) ◽  
pp. 327-336 ◽  
Author(s):  
Carl R. Harrell ◽  
Marina Gazdic ◽  
Crissy Fellabaum ◽  
Nemanja Jovicic ◽  
Valentin Djonov ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Animal Models ◽  
Amniotic Fluid ◽  
Therapeutic Potential ◽  
Inflammatory Diseases ◽  
Therapeutic Effects ◽  
Differentiation Potential ◽  
Differentiation Capacity ◽  
Cell Based Therapy

Background: Amniotic Fluid Derived Mesenchymal Stem Cells (AF-MSCs) are adult, fibroblast- like, self-renewable, multipotent stem cells. During the last decade, the therapeutic potential of AF-MSCs, based on their huge differentiation capacity and immunomodulatory characteristics, has been extensively explored in animal models of degenerative and inflammatory diseases. Objective: In order to describe molecular mechanisms responsible for the therapeutic effects of AFMSCs, we summarized current knowledge about phenotype, differentiation potential and immunosuppressive properties of AF-MSCs. Methods: An extensive literature review was carried out in March 2018 across several databases (MEDLINE, EMBASE, Google Scholar), from 1990 to present. Keywords used in the selection were: “amniotic fluid derived mesenchymal stem cells”, “cell-therapy”, “degenerative diseases”, “inflammatory diseases”, “regeneration”, “immunosuppression”. Studies that emphasized molecular and cellular mechanisms responsible for AF-MSC-based therapy were analyzed in this review. Results: AF-MSCs have huge differentiation and immunosuppressive potential. AF-MSCs are capable of generating cells of mesodermal origin (chondrocytes, osteocytes and adipocytes), neural cells, hepatocytes, alveolar epithelial cells, insulin-producing cells, cardiomyocytes and germ cells. AF-MSCs, in juxtacrine or paracrine manner, regulate proliferation, activation and effector function of immune cells. Due to their huge differentiation capacity and immunosuppressive characteristic, transplantation of AFMSCs showed beneficent effects in animal models of degenerative and inflammatory diseases of nervous, respiratory, urogenital, cardiovascular and gastrointestinal system. Conclusion: Considering the fact that amniotic fluid is obtained through routine prenatal diagnosis, with minimal invasive procedure and without ethical concerns, AF-MSCs represents a valuable source for cell-based therapy of organ-specific or systemic degenerative and inflammatory diseases.

Stem Cells and Endometrial Regeneration: From Basic Research to Clinical Trial

2019 ◽  
Vol 14 (4) ◽  
pp. 293-304 ◽  
Author(s):  
Xinxin Zhu ◽  
Bruno Péault ◽  
Guijun Yan ◽  
Haixiang Sun ◽  
Yali Hu ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Basic Research ◽  
Alternative Source ◽  
Endometrial Stem Cells ◽  
Endometrial Injury ◽  
Marrow Mesenchymal Stem Cells ◽  
Monthly Changes

Monthly changes in the endometrial cycle indicate the presence of endometrial stem cells. In recent years, various stem cells that exist in the endometrium have been identified and characterized. Additionally, many studies have shown that Bone Marrow Mesenchymal Stem Cells (BM-MSCs) provide an alternative source for regenerating the endometrium and repairing endometrial injury. This review discusses the origin of endometrial stem cells, the characteristics and main biomarkers among five types of putative endometrial stem cells, applications of endometrium-derived stem cells and menstrual blood-derived stem cells, the association between BM-MSCs and endometrial stem cells, and progress in repairing endometrial injury.

scholarly journals Extracellular Vesicles of Mesenchymal Stem Cells: Therapeutic Properties Discovered with Extraordinary SuccessOK

Biomedicines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 667
Author(s):  
Gabriella Racchetti ◽  
Jacopo Meldolesi
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Immune Responses ◽  
Extracellular Vesicles ◽  
Immune Regulation ◽  
Great Increase ◽  
The Body ◽  
Cell Aging ◽  
Therapeutic Effects ◽  
Therapeutic Properties

Mesenchymal stem cells (MSCs), the cells distributed in the stromas of the body, are known for various properties including replication, the potential of various differentiations, the immune-related processes including inflammation. About two decades ago, these cells were shown to play relevant roles in the therapy of numerous diseases, dependent on their immune regulation and their release of cytokines and growth factors, with ensuing activation of favorable enzymes and processes. Such discovery induced great increase of their investigation. Soon thereafter, however, it became clear that therapeutic actions of MSCs are risky, accompanied by serious drawbacks and defects. MSC therapy has been therefore reduced to a few diseases, replaced for the others by their extracellular vesicles, the MSC-EVs. The latter vesicles recapitulate most therapeutic actions of MSCs, with equal or even better efficacies and without the serious drawbacks of the parent cells. In addition, MSC-EVs are characterized by many advantages, among which are their heterogeneities dependent on the stromas of origin, the alleviation of cell aging, the regulation of immune responses and inflammation. Here we illustrate the MSC-EV therapeutic effects, largely mediated by specific miRNAs, covering various diseases and pathological processes occurring in the bones, heart and vessels, kidney, and brain. MSC-EVs operate also on the development of cancers and on COVID-19, where they alleviate the organ lesions induced by the virus. Therapy by MSC-EVs can be improved by combination of their innate potential to engineering processes inducing precise targeting and transfer of drugs. The unique properties of MSC-EVs explain their intense studies, carried out with extraordinary success. Although not yet developed to clinical practice, the perspectives for proximal future are encouraging.

scholarly journals Bmi1 Augments Proliferation and Survival of Cortical Bone-Derived Stem Cells after Injury through Novel Epigenetic Signaling via Histone 3 Regulation

2021 ◽  
Vol 22 (15) ◽  
pp. 7813
Author(s):  
Lindsay Kraus ◽  
Chris Bryan ◽  
Marcus Wagner ◽  
Tabito Kino ◽  
Melissa Gunchenko ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Stem Cells ◽  
Dna Damage ◽  
Stem Cell ◽  
Histone Modification ◽  
Epigenetic Regulation ◽  
Critical Role ◽  
Proliferative Potential ◽  
Therapeutic Effects ◽  
Histone 3

Ischemic heart disease can lead to myocardial infarction (MI), a major cause of morbidity and mortality worldwide. Multiple stem cell types have been safely transferred into failing human hearts, but the overall clinical cardiovascular benefits have been modest. Therefore, there is a dire need to understand the basic biology of stem cells to enhance therapeutic effects. Bmi1 is part of the polycomb repressive complex 1 (PRC1) that is involved in different processes including proliferation, survival and differentiation of stem cells. We isolated cortical bones stem cells (CBSCs) from bone stroma, and they express significantly high levels of Bmi1 compared to mesenchymal stem cells (MSCs) and cardiac-derived stem cells (CDCs). Using lentiviral transduction, Bmi1 was knocked down in the CBSCs to determine the effect of loss of Bmi1 on proliferation and survival potential with or without Bmi1 in CBSCs. Our data show that with the loss of Bmi1, there is a decrease in CBSC ability to proliferate and survive during stress. This loss of functionality is attributed to changes in histone modification, specifically histone 3 lysine 27 (H3K27). Without the proper epigenetic regulation, due to the loss of the polycomb protein in CBSCs, there is a significant decrease in cell cycle proteins, including Cyclin B, E2F, and WEE as well as an increase in DNA damage genes, including ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR). In conclusion, in the absence of Bmi1, CBSCs lose their proliferative potential, have increased DNA damage and apoptosis, and more cell cycle arrest due to changes in epigenetic modifications. Consequently, Bmi1 plays a critical role in stem cell proliferation and survival through cell cycle regulation, specifically in the CBSCs. This regulation is associated with the histone modification and regulation of Bmi1, therefore indicating a novel mechanism of Bmi1 and the epigenetic regulation of stem cells.

Sign in / Sign up

Export Citation Format

Share Document